Acute intermittent porphyria

Acute intermittent porphyria is a rare, or orphan, genetic disease, caused by the inability of the liver to metabolize porphyrin precursors. It presents with painful intermittent pain and may cause major neurological damage.

Crisis in patients may be caused by some medications, strict dieting or prolonged stress. However, the main triggers are female hormones associated with the menstrual cycle, and so the disorder occurs particularly in young women with weighty work and family responsibilities.

There is currently no specific treatment for this disease that, on occasion, can lead to chronic pain and hypertension, significant neurological damage and even liver and / or kidney transplantation may be necessary.

Cima researchers accumulate more than 30 years of experience in the study of porphyria. They collaborate with the Hospital of Navarra, the Hospital de Tudela and other national and international groups dedicated to porphyria in order to better understand mechanisms related to the disease and to characterize new markers for the early detection and evolution of the attacks.

One of the main objectives of the Hepatology Program is to develop new therapeutic strategies based on gene therapy and innovative biotechnological products.

Team

  • Antonio Fontanellas Romá Antonio Fontanellas Romá
    Researcher
    Telephone:948 194700 Extension:81 4009 Email:
    afontanellas@unav.es
  • Iranzu Serrano Mendioroz Iranzu Serrano Mendioroz
    Laboratory Technician
    Telephone:948 174700 Extension:81 4008 Email:
    ismendioroz@unav.es
  • Ana Sampedro Pascual Ana Sampedro Pascual
    Laboratory Technician
    Telephone:948 194700 Extension:81 4008 Email:
    asampedro@unav.es
  • Daniel Jericó Asenjo Daniel Jericó Asenjo
    PhD student
    Telephone:948 194700 Extension:81 4008 Email:
    djerico@alumni.unav.es
  • Karol Marcela Córdoba Quiñones Karol Marcela Córdoba Quiñones
    PhD student
    Telephone:948 194700 Extension:81 4008 Email:
    kcordoba@alumni.unav.es


"One of our main objectives is to develop new therapeutic strategies based on gene therapy and innovative biotechnological products", Dr. Antonio Fontanellas.

Contact

Contact:
Cibeles Pinto
Avda. Pío XII, 55
31.008 Pamplona
Spain

(+34) 948 194 700 Ext. 4012
mcpinto@unav.es